Study of the Relationship between Heme Oxygenase-1, Interleukins (6, 12) and Coenzyme Q10 in Iraqi Pediatric Patients with Chronic Myeloid Leukemia

Mustafa Yassin Khalf and Wasan Nazhan Hussein

References:

1. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000.
2. I. N. Olver, “Prevention of breast cancer,” Med. J. Aust., vol. 205, no. 10, pp. 475–479, Nov. 2016, doi: 10.5694/MJA16.01007.
3. Z. Abbas and S. Rehman, “An overview of cancer treatment modalities,” in Neoplasm. London, U.K.: IntechOpen, 2018.
4. A. Amaro et al., “The biology of uveal melanoma,” Cancer Metastasis Rev., vol. 36, no. 1, pp. 109–140, 2017.
5. C.-H. Pui, W. L. Carroll, S. Meshinchi, and R. J. Arceci, “Biology, risk stratification, and therapy of pediatric acute leukemias: an update,” J. Clin. Oncol., vol. 29, no. 5, p. 551, 2011.
6. W. Lockwood, “Leukemia: AML, CML, ALL and CLL,” 2019.
7. J. E. Niederhuber et al., Abeloff's Clinical Oncology, 6th ed. Philadelphia, PA, USA: Elsevier, 2020. [Online]. Available: https://www.clinicalkey.com, Accessed Oct. 16, 2020.
8. T. Terwilliger and M. Abdul-Hay, “Acute lymphoblastic leukemia: a comprehensive review and 2017 update,” Blood Cancer J., vol. 7, no. 6, pp. e577–e577, 2017.
9. L. D. Bastian, “Clinical and cytogenetic features of leukemias in children treated in the University Hospital of Split from 2000 to 2017,” M.S. thesis, Univ. Split, Split, Croatia, 2018.
10. C. L. Sawyers, “Chronic myeloid leukemia,” N. Engl. J. Med., vol. 340, no. 17, pp. 1330–1340, 1999.
11. M. Hallek, “Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment,” Am. J. Hematol., vol. 94, no. 11, pp. 1266–1287, 2019.
12. L. L. Dunn et al., “New insights into intracellular locations and functions of heme oxygenase-1,” Antioxid. Redox Signal., vol. 20, no. 11, pp. 1723–1742, 2014.
13. T. D. Hinds Jr. et al., “Rats genetically selected for high aerobic exercise capacity have elevated plasma bilirubin by upregulation of hepatic biliverdin reductase-A (BVRA) and suppression of UGT1A1,” Antioxidants, vol. 9, no. 9, p. 889, 2020.
14. J. Wang and P. R. Ortiz de Montellano, “The binding sites on human heme oxygenase-1 for cytochrome P450 reductase and biliverdin reductase,” J. Biol. Chem., vol. 278, no. 22, pp. 20069–20076, 2003.
15. N. Batra et al., “The HMOX1 pathway as a promising target for the treatment and prevention of SARS-CoV-2 of 2019,” Int. J. Mol. Sci., vol. 21, no. 17, p. 6412, 2020.
16. S. W. Ryter, J. Alam, and A. M. K. Choi, “Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications,” Physiol. Rev., vol. 86, no. 2, pp. 583–650, 2006.
17. D. P. Converso et al., “HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism,” FASEB J., vol. 20, no. 8, pp. 1236–1238, 2006.
18. S. Li et al., “Protective role of heme oxygenase-1 in fatty liver ischemia–reperfusion injury,” Med. Mol. Morphol., vol. 52, no. 2, pp. 61–72, 2019.
19. J. D. Belcher et al., “Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction,” PLoS One, vol. 13, no. 4, p. e0196455, 2018.
20. A. Kathagen-Buhmann et al., “Glycolysis and the pentose pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation,” Neuro Oncol., vol. 18, no. 9, pp. 1219–1229, 2016.
21. H. P. Kim et al., “Caveolae compartmentalization of heme oxygenase-1 in endothelial cells,” FASEB J., vol. 18, no. 10, pp. 1080–1089, 2004.
22. F. Vallelian et al., “Proteasome inhibition and oxidative reactions disrupt cellular homeostasis during heme stress,” Cell Death Differ., vol. 22, no. 4, pp. 597–611, 2015.
23. S. Rose-John, “Interleukin-6 family cytokines,” Cold Spring Harb. Perspect. Biol., vol. 10, no. 2, pp. 1–17, 2018.
24. T. Tanaka, M. Narazaki, A. Ogata, and T. Kishimoto, “A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy,” Semin. Immunol., vol. 26, no. 1, pp. 88–96, 2014.
25. T. Tanaka, M. Narazaki, and T. Kishimoto, “Interleukin (IL-6) immunotherapy,” Immunotherapy, pp. 1–15, 2018.
26. E. M. Cheng, N. W. Tsarovsky, P. M. Sondel, and A. L. Rakhmilevich, “Interleukin 12 as an in situ cancer vaccine component: a review,” Cancer Immunol. Immunother., vol. 71, no. 9, pp. 2057–2065, 2022.
27. D. M. Weiner, J. S. Durgin, M. Wysocka, and A. H. Rook, “The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches,” J. Am. Acad. Dermatol., vol. 84, no. 3, pp. 597–604, 2021.
28. L. S. Guedes and R. M. Martinez, “An overview on topical administration of carotenoids and coenzyme Q10 loaded in lipid nanoparticles,” 2021.
29. E. C. Naylor and R. E. B. Watson, “Molecular aspects of skin ageing,” 2011.
30. I. P. de Barcelos and R. H. Haas, “CoQ10 and aging,” 2019.
31. K. Žmitek and J. Žmitek, “Effects of a combination of water-soluble coenzyme Q10 and collagen on skin parameters and condition: Results of a randomised, placebo-controlled, double-blind study,” 2020.
32. “Topical treatment with coenzyme Q10-containing formulas improves skin’s Q10 level and provides antioxidative effects,” 2015.
33. K. Bukowska-Strakova et al., “Heme oxygenase 1 affects granulopoiesis in mice through control of myelocyte proliferation,” Immunobiology, vol. 222, pp. 506–517, 2017.
34. K. Bukowska-Strakova et al., “Role of HMOX1 promoter genetic variants in chemoresistance and chemotherapy induced neutropenia in children with acute lymphoblastic leukemia,” Int. J. Mol. Sci., vol. 22, no. 3, p. 988, 2021.
35. C. Feng et al., “Heme oxygenase-1 inhibits the cytotoxicity of natural killer cells to acute myeloid leukemia by downregulating human leukocyte antigen-C,” Cytotherapy, vol. 25, no. 7, pp. 728–738, 2023.
36. M. Nitti, C. Ivaldo, N. Traverso, and A. L. Furfaro, “Clinical significance of heme oxygenase 1 in tumor progression,” Antioxidants, vol. 10, no. 5, p. 789, 2021.
37. G. Sferrazzo et al., “Heme oxygenase-1 in central nervous system malignancies,” J. Clin. Med., vol. 9, no. 5, p. 1562, 2020.
38. A. R. Vachanaram, “Myeloid derived suppressor cells (MDSCs), heme-oxygenase-1 (HO-1) and C88 expression in circulating monocytes: a study of impact on outcome in advanced cancer patients treated with immune checkpoint inhibitors (ICIs),” 2023.
39. R. A. Alshali, “The potential chemotherapeutic effect of coenzyme Q10 against liver injury in a leukemia rat model by 7,12-dimethylbenzanthracene: Histological and morphometric study,” 2024.
40. L. Roffe, K. Schmidt, and E. Ernst, “Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: A systematic review,” J. Clin. Oncol., vol. 22, no. 21, pp. 4418–4424, 2004.
41. R. A. Hassan and M. M. El-Masry, “Levels of interleukins 12 (IL-12) and 13 (IL-13), hepatitis B and C serology, and blood cultures among acute myeloid leukemia (AML) patients in Egypt,” J. Venom. Anim. Toxins Incl. Trop. Dis., vol. 17, pp. 293–299, 2011.
42. Y. Xu, X. Sun, and Y. Tong, “Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity,” Discover Oncol., vol. 15, no. 1, p. 170, 2024.
43. J. A. Stinson et al., “Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs,” Clin. Cancer Res., vol. 30, no. 18, pp. 4029–4043, 2024.
44. R. A. Al-Qaisi, A. M. Al-Gebori, and M. H. M. Alosami, “Evaluation of bone turnover markers in patients with acute and chronic leukemia,” Indian J. Clin. Biochem., vol. 39, no. 3, pp. 401–407, 2024.
45. M. Q. Mohammed, A. H. Alwan, and A. A. Almukhtar, “Estimation of serum TLR-9, TNF-α, and IL-6 levels in the Iraqi patients diagnosed as acute myelogenous leukemia,” Baghdad Sci. J., vol. 21, no. 7, p. 2182, 2024.
46. R. Tamer, Ş. S. O. Ünal, and C. Y. Yozgat, “Elevated interleukin-6 levels as a potential marker of neonatal morbidity in full-term infants with polycythemia: A prospective study,” J. Pediatr. Hematol. Oncol., 2024.
47. S. P. Lin et al., “The predictive utility of cytokines, procalcitonin and C-reactive protein among febrile pediatric hematology and oncology patients with severe sepsis or septic shock,” Pediatr. Hematol. Oncol., vol. 41, no. 1, pp. 1–14, 2024.